Nanotechnology intervention of the microbiome for cancer therapy

The microbiome is emerging as a key player and driver of cancer. Traditional modalities to manipulate the microbiome (for example, antibiotics, probiotics and microbiota transplants) have been shown to improve efficacy of cancer therapies in some cases, but issues such as collateral damage to the commensal microbiota and consistency of these approaches motivates efforts towards developing new technologies specifically designed for the microbiome–cancer interface. Considering the success of nanotechnology in transforming cancer diagnostics and treatment, nanotechnologies capable of manipulating interactions that occur across microscopic and molecular length scales in the microbiome and the tumour microenvironment have the potential to provide innovative strategies for cancer treatment. As such, opportunities at the intersection of nanotechnology, the microbiome and cancer are massive. In this Review, we highlight key opportunistic areas for applying nanotechnologies towards manipulating the microbiome for the treatment of cancer, give an overview of seminal work and discuss future challenges and our perspective on this emerging area. This review highlights key opportunistic areas for applying nanotechnologies towards the manipulation of the microbiome for the treatment of cancer, gives an overview of seminal work and discusses future challenges and our perspective on this emerging area.

[1]  F. Marincola,et al.  Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment , 2013, Science.

[2]  Timothy K Lu,et al.  Microbiome therapeutics - Advances and challenges. , 2016, Advanced drug delivery reviews.

[3]  Manish Kohli,et al.  Nanoparticles for combination drug therapy. , 2013, ACS nano.

[4]  S. Grivennikov,et al.  Microbiome, Inflammation, and Cancer , 2014, Cancer journal.

[5]  Nathalie M. Delzenne,et al.  Prebiotic effects: metabolic and health benefits , 2010, British Journal of Nutrition.

[6]  R. Langer,et al.  Transepithelial Transport of Fc-Targeted Nanoparticles by the Neonatal Fc Receptor for Oral Delivery , 2013, Science Translational Medicine.

[7]  R Balfour Sartor,et al.  Therapeutic Manipulation of the Microbiome in IBD: Current Results and Future Approaches , 2015, Current Treatment Options in Gastroenterology.

[8]  H. Bouwmeester,et al.  Effects of food‐borne nanomaterials on gastrointestinal tissues and microbiota , 2017, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[9]  J. Brown,et al.  Exploiting tumour hypoxia in cancer treatment , 2004, Nature Reviews Cancer.

[10]  Samir Mitragotri,et al.  Nanoparticles in the clinic: An update , 2019, Bioengineering & translational medicine.

[11]  E. Komulainen,et al.  Emergence of penicillin resistance among Fusobacterium nucleatum populations of commensal oral flora during early childhood. , 2003, The Journal of antimicrobial chemotherapy.

[12]  B. Helmink,et al.  The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy. , 2018, Cancer cell.

[13]  Joseph M. DeSimone,et al.  Strategies in the design of nanoparticles for therapeutic applications , 2010, Nature Reviews Drug Discovery.

[14]  J. Gerber,et al.  Antibiotics, pediatric dysbiosis, and disease. , 2015, Cell host & microbe.

[15]  Laurence Zitvogel,et al.  Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors , 2018, Science.

[16]  B. Zhang,et al.  Biomimetic nanoparticles for inflammation targeting , 2017, Acta pharmaceutica Sinica. B.

[17]  S. Mitragotri,et al.  Nanoparticles in the clinic , 2016, Bioengineering & translational medicine.

[18]  J. Hanes,et al.  Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. , 2009, Advanced drug delivery reviews.

[19]  K. Memarzadeh,et al.  Antimicrobial activity of nanoparticulate metal oxides against peri-implantitis pathogens. , 2012, International journal of antimicrobial agents.

[20]  Paula T Hammond,et al.  Layer-by-layer nanoparticles with a pH-sheddable layer for in vivo targeting of tumor hypoxia. , 2011, ACS nano.

[21]  M. Hatakeyama.  Oncogenic mechanisms of the Helicobacter pylori CagA protein , 2004, Nature Reviews Cancer.

[22]  R. Knight,et al.  The Human Microbiome Project , 2007, Nature.

[23]  J. Karp,et al.  Nanocarriers as an Emerging Platform for Cancer Therapy , 2022 .

[24]  S. Ghosh,et al.  Understanding the Holobiont: How Microbial Metabolites Affect Human Health and Shape the Immune System. , 2017, Cell metabolism.

[25]  F. Ginhoux,et al.  Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota , 2015, Science.

[26]  O. Farokhzad,et al.  Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release. , 2016, Chemical reviews.

[27]  Kunyu Qiu,et al.  Inorganic nanoparticles and the microbiome , 2018, Nano Research.

[28]  Xiong Ma,et al.  The microbiome and autoimmunity: a paradigm from the gut–liver axis , 2018, Cellular & Molecular Immunology.

[29]  Carme Pastells,et al.  Nanoparticle-based biosensors for detection of pathogenic bacteria , 2009 .

[30]  Donna Neuberg,et al.  Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer , 2017, Science.

[31]  M. R. Rubinstein,et al.  Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin. , 2013, Cell host & microbe.

[32]  M. Redinbo,et al.  The role of the microbiome in cancer development and therapy , 2017, CA: a cancer journal for clinicians.

[33]  Yunsheng Yang,et al.  Recent Insights into Antibiotic Resistance in Helicobacter pylori Eradication , 2012, Gastroenterology research and practice.

[34]  Jeff Hasty,et al.  Programmable probiotics for detection of cancer in urine , 2015, Science Translational Medicine.

[35]  A. J. Tavares,et al.  Analysis of nanoparticle delivery to tumours , 2016 .

[36]  M. Blaser,et al.  Antibiotics in early life alter the murine colonic microbiome and adiposity , 2012, Nature.

[37]  Christine B. Peterson,et al.  Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes , 2019, Cell.

[38]  Belgin Dogan,et al.  Intestinal Inflammation Targets Cancer-Inducing Activity of the Microbiota , 2012, Science.

[39]  Qingsheng Wu,et al.  Synergistic antibacterial effects of β-lactam antibiotic combined with silver nanoparticles , 2005 .

[40]  J. McQuade,et al.  Modulating the microbiome to improve therapeutic response in cancer. , 2019, The Lancet. Oncology.

[41]  Hong-Xia Wang,et al.  Differential anticancer drug delivery with a nanogel sensitive to bacteria-accumulated tumor artificial environment. , 2013, ACS nano.

[42]  Liangfang Zhang,et al.  Nanoparticle approaches against bacterial infections. , 2014, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[43]  Dennis E Discher,et al.  Minimal " Self " Peptides That Inhibit Phagocytic Clearance and Enhance Delivery of Nanoparticles References and Notes , 2022 .

[44]  Huidong Shi,et al.  Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. , 2014, Immunity.

[45]  C. Tropini,et al.  The Gut Microbiome: Connecting Spatial Organization to Function. , 2017, Cell host & microbe.

[46]  R. Weissleder,et al.  Imaging in the era of molecular oncology , 2008, Nature.

[47]  D. Plichta,et al.  A defined commensal consortium elicits CD8 T cells and anti-cancer immunity , 2019, Nature.

[48]  L. Campagnolo,et al.  New frontiers in nanotoxicology: Gut microbiota/microbiome-mediated effects of engineered nanomaterials. , 2016, Toxicology and applied pharmacology.

[49]  Leaf Huang,et al.  Pharmacokinetics and biodistribution of nanoparticles. , 2008, Molecular pharmaceutics.

[50]  N. K. Jain,et al.  Amoxicillin, clarithromycin, and omeprazole based targeted nanoparticles for the treatment of H. pylori , 2009, Journal of drug targeting.

[51]  Jennifer Sturgis,et al.  Bacteria-mediated delivery of nanoparticles and cargo into cells. , 2007, Nature nanotechnology.

[52]  Warren C W Chan,et al.  The effect of nanoparticle size, shape, and surface chemistry on biological systems. , 2012, Annual review of biomedical engineering.

[53]  J. Moon,et al.  Hyaluronic acid-bilirubin nanomedicine for targeted modulation of dysregulated intestinal barrier, microbiome, and immune responses in colitis. , 2019, Nature Materials.

[54]  S. Pushalkar,et al.  The Pancreatic Cancer Microbiome Promotes Oncogenesis by Induction of Innate and Adaptive Immune Suppression. , 2018, Cancer discovery.

[55]  Rong Chen,et al.  Size-dependent antibacterial activities of silver nanoparticles against oral anaerobic pathogenic bacteria , 2013, Journal of Materials Science: Materials in Medicine.

[56]  Susan Hua,et al.  Advances in oral nano-delivery systems for colon targeted drug delivery in inflammatory bowel disease: selective targeting to diseased versus healthy tissue. , 2015, Nanomedicine : nanotechnology, biology, and medicine.

[57]  Hongjuan Zhao,et al.  A Probiotic Spore‐Based Oral Autonomous Nanoparticles Generator for Cancer Therapy , 2019, Advanced materials.

[58]  Ronnie H. Fang,et al.  Nanoparticle biointerfacing via platelet membrane cloaking , 2015, Nature.

[59]  N. Forbes.  Engineering the perfect (bacterial) cancer therapy , 2010, Nature Reviews Cancer.

[60]  L. Zitvogel,et al.  Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[61]  David Julian McClements,et al.  Is nano safe in foods? Establishing the factors impacting the gastrointestinal fate and toxicity of organic and inorganic food-grade nanoparticles , 2017, npj Science of Food.

[62]  Raul Rabadan,et al.  Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. , 2012, Cancer cell.

[63]  M. Bissonnette,et al.  The Microbe-Derived Short Chain Fatty Acid Butyrate Targets miRNA-Dependent p21 Gene Expression in Human Colon Cancer , 2011, PloS one.

[64]  Yuan Ping,et al.  Engineering nanoparticle-coated bacteria as oral DNA vaccines for cancer immunotherapy. , 2015, Nano letters.

[65]  Y. Shoenfeld,et al.  The microbiome in autoimmune diseases , 2019, Clinical and experimental immunology.

[66]  Leaf Huang,et al.  Local and transient gene expression primes the liver to resist cancer metastasis , 2016, Science Translational Medicine.

[67]  Ava M Vargason,et al.  Clinical translation of microbe‐based therapies: Current clinical landscape and preclinical outlook , 2018, Bioengineering & translational medicine.

[68]  J. Morris.  Faculty Opinions recommendation of Understanding the holobiont: how microbial metabolites affect human health and shape the immune system. , 2018, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[69]  Morteza Mahmoudi,et al.  Antibacterial properties of nanoparticles. , 2012, Trends in biotechnology.

[70]  Jason B. Williams,et al.  Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy , 2015, Science.

[71]  Noam Shental,et al.  Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine , 2017, Science.

[72]  Mauro Ferrari,et al.  Principles of nanoparticle design for overcoming biological barriers to drug delivery , 2015, Nature Biotechnology.

[73]  James J Moon,et al.  Engineering Nano‐ and Microparticles to Tune Immunity , 2012, Advanced materials.

[74]  K. Johnson.  An Update. , 1984, Journal of food protection.

[75]  M. Sitti,et al.  Bioengineered and biohybrid bacteria-based systems for drug delivery. , 2016, Advanced drug delivery reviews.

[76]  V. Young.  Therapeutic manipulation of the microbiota: past, present, and considerations for the future. , 2016, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[77]  Zi-Hao Li,et al.  Bacteria-Mediated Tumor Therapy Utilizing Photothermally-Controlled TNF-α Expression via Oral Administration. , 2018, Nano letters.

[78]  Liping Zhao,et al.  Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers , 2011, The ISME Journal.

[79]  R. Schwabe,et al.  The Microbiome and Cancer , 2021, Gut Feelings.

[80]  Leaf Huang,et al.  Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap , 2018, Nature Communications.

[81]  Nicholas A Peppas,et al.  Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. , 2006, International journal of pharmaceutics.

[82]  S. Abedon,et al.  Phage therapy in clinical practice: treatment of human infections. , 2010, Current pharmaceutical biotechnology.

[83]  Eric Vivier,et al.  The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide , 2013, Science.

[84]  Leaf Huang,et al.  Trapping of Lipopolysaccharide to Promote Immunotherapy against Colorectal Cancer and Attenuate Liver Metastasis , 2018, Advanced materials.

[85]  S. Tsuruta,et al.  Baseline Serum Cholesterol Is Associated with a Response to Pegylated Interferon Alfa-2b and Ribavirin Therapy for Chronic Hepatitis C Genotype 2 , 2012, Gastroenterology research and practice.

[86]  G. Gao,et al.  Dysbiosis Signature of Fecal Microbiota in Colorectal Cancer Patients , 2013, Microbial Ecology.

[87]  Patrick Couvreur,et al.  Stimuli-responsive nanocarriers for drug delivery. , 2013, Nature materials.

[88]  M. Meyerson,et al.  Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. , 2013, Cell host & microbe.

[89]  Fangfang Guo,et al.  Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy , 2017, Cell.

[90]  Ronnie H. Fang,et al.  Coating Nanoparticles with Gastric Epithelial Cell Membrane for Targeted Antibiotic Delivery against Helicobacter pylori Infection , 2018, Advanced therapeutics.

[91]  Lawrence A. David,et al.  Diet rapidly and reproducibly alters the human gut microbiome , 2013, Nature.

[92]  D. Zheng,et al.  Phage-guided modulation of the gut microbiota of mouse models of colorectal cancer augments their responses to chemotherapy , 2019, Nature Biomedical Engineering.

[93]  H. Maeda,et al.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.

[94]  S. Mazmanian,et al.  Emerging evidence linking the gut microbiome to neurologic disorders , 2018, Genome Medicine.

[95]  Xiaoyang Xu,et al.  Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. , 2014, Advanced drug delivery reviews.

[96]  S. N. Bhatia,et al.  Synthetic and living micropropellers for convection-enhanced nanoparticle transport , 2019, Science Advances.

[97]  B. Helmink,et al.  The microbiome, cancer, and cancer therapy , 2019, Nature Medicine.

[98]  Fred C Tenover,et al.  Mechanisms of antimicrobial resistance in bacteria. , 2006, The American journal of medicine.

[99]  J Licinio,et al.  From gut dysbiosis to altered brain function and mental illness: mechanisms and pathways , 2016, Molecular Psychiatry.

[100]  U. Alon,et al.  Robustness in bacterial chemotaxis , 2022 .